Expertise in
21
conditions

Dr. Stephen T. Oh

Hematology
Washington University
660 S Euclid Ave, 
Saint Louis, MO 
Accepting New Patients
Expertise in
21
conditions
Washington University
660 S Euclid Ave, 
Saint Louis, MO 

Overview

Stephen Oh is a Hematologist practicing medicine in Saint Louis, Missouri.

Dr. Oh is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Myeloproliferative Neoplasms (MPN), Essential Thrombocythemia, Polycythemia Vera, and Pancreaticoduodenectomy.

He is actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 13 clinical trials. Dr. Oh is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish St Peters Hospital
Barnes Jewish Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Washington University
660 S Euclid Ave, Saint Louis, MO 63110

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2026
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma
Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma
Enrollment Status: Completed
Publish Date: January 03, 2025
Intervention Type: Procedure, Drug, Radiation
Study Phase: Phase 1
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
Enrollment Status: Terminated
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drugs: Fostamatinib, Ruxolitinib
Study Phase: Phase 2
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
Enrollment Status: Terminated
Publish Date: January 06, 2022
Intervention Type: Drug, Procedure
Study Drugs: Pevonedistat, Ruxolitinib
Study Phase: Phase 1
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Enrollment Status: Completed
Publish Date: August 17, 2021
Intervention Type: Biological
Study Phase: Phase 2
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Enrollment Status: Completed
Publish Date: November 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

138 Total Publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Expertise in
28
conditions
Dr. Brad S. Kahl
Hematology
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-747-1171
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brad Kahl is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Kahl is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kahl is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University School Of Medicine

4921 Parkview Pl, 
Saint Louis, MO 
 (0.2 miles away)
314-747-1171
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Neha Mehta-Shah is a Hematologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Mehta-Shah is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mehta-Shah is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (0.8 miles away)
314-454-8304
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Geoffrey Uy is a Hematologist practicing medicine in Saint Louis, Missouri. Dr. Uy is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Uy is currently accepting new patients.

Frequently Asked Questions about Dr. Stephen T. Oh

How do I make an appointment with Dr. Stephen T. Oh?

You can book an appointment with Dr. Stephen T. Oh by calling their office at 314-362-7216. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Stephen T. Oh a top-rated expert for Myelofibrosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Stephen T. Oh is classified as an Elite expert for Myelofibrosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Stephen T. Oh specialize in?

While Dr. Stephen T. Oh is a Hematology, they have specific expertise in Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Essential Thrombocythemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Stephen T. Oh participate in research or clinical trials?

Yes. Dr. Stephen T. Oh has published 138 articles and abstracts on conditions like Myelofibrosis. You can view a list of Dr. Stephen T. Oh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Stephen T. Oh accept my insurance?

Dr. Stephen T. Oh accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-362-7216 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oh's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile